Advertisement
ARQT vs PTCT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and PTCT is a Buy.
Aroon Indicator for ARQT shows an upward move is likely
ARQT's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARQT moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 58 of 69 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ARQT broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.403) is normal, around the industry mean (3.051). ARQT's P/E Ratio (154.773) is considerably higher than the industry average of (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (439.647).
PTCT in upward trend: price rose above 50-day moving average on November 03, 2026
PTCT moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on PTCT as a result. In 64 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for PTCT just turned positive on October 20, 2026. Looking at past instances where PTCT's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Following a +13.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTCT advanced for three days, in 217 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 64 cases where PTCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
PTCT broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PTCT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-34.810) is normal, around the industry mean (3.051). PTCT has a moderately low P/E Ratio (-102.940) as compared to the industry average of (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (6.094) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. PTCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ARQT | PTCT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 76 | 53 | |
SMR RATING 1..100 | 54 | 100 | |
PRICE GROWTH RATING 1..100 | 37 | 69 | |
P/E GROWTH RATING 1..100 | 26 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PTCT's Valuation (1) in the Biotechnology industry is significantly better than the same rating for ARQT (99) in the null industry. This means that PTCT’s stock grew significantly faster than ARQT’s over the last 12 months.
PTCT's Profit vs Risk Rating (53) in the Biotechnology industry is in the same range as ARQT (76) in the null industry. This means that PTCT’s stock grew similarly to ARQT’s over the last 12 months.
ARQT's SMR Rating (54) in the null industry is somewhat better than the same rating for PTCT (100) in the Biotechnology industry. This means that ARQT’s stock grew somewhat faster than PTCT’s over the last 12 months.
ARQT's Price Growth Rating (37) in the null industry is in the same range as PTCT (69) in the Biotechnology industry. This means that ARQT’s stock grew similarly to PTCT’s over the last 12 months.
ARQT's P/E Growth Rating (26) in the null industry is significantly better than the same rating for PTCT (100) in the Biotechnology industry. This means that ARQT’s stock grew significantly faster than PTCT’s over the last 12 months.
| ARQT | PTCT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | N/A |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| Advances ODDS (%) | 6 days ago 85% | 2 days ago 79% |
| Declines ODDS (%) | 8 days ago 87% | 22 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARQT’s FA Score shows that 1 FA rating(s) are green while PTCT’s FA Score has 1 green FA rating(s).
- ARQT’s FA Score: 1 green, 4 red.
- PTCT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARQT’s TA Score shows that 5 TA indicator(s) are bullish while PTCT’s TA Score has 4 bullish TA indicator(s).
- ARQT’s TA Score: 5 bullish, 5 bearish.
- PTCT’s TA Score: 4 bullish, 4 bearish.
Price Growth
ARQT (@Biotechnology) experienced а +1.01% price change this week, while PTCT (@Biotechnology) price change was +9.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.
Reported Earning Dates
ARQT is expected to report earnings on Nov 04, 2026.
PTCT is expected to report earnings on Feb 23, 2027.
Industries' Descriptions
@Biotechnology (-3.31% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARQT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | +2.37% | ||
| XNCR - ARQT | 48% Loosely correlated | +3.30% | ||
| PTGX - ARQT | 46% Loosely correlated | +0.62% | ||
| PTCT - ARQT | 44% Loosely correlated | +11.89% | ||
| TRDA - ARQT | 42% Loosely correlated | -7.63% | ||
| TGTX - ARQT | 42% Loosely correlated | +1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPFP | 49.32 | 0.12 | +0.25% |
| JPMorgan Managed Futures Plus ETF (JPFP) | |||
| TXUG | 25.98 | 0.06 | +0.23% |
| Thornburg International Growth Fund ETF (TXUG) | |||
| BYLD | 21.75 | -0.09 | -0.41% |
| iShares Yield Optimized Bond ETF (BYLD) | |||
| IBHL | 24.31 | -0.10 | -0.42% |
| iShares iBonds 2032 Term High Yield and Income ETF (IBHL) | |||
| FENY | 36.59 | -0.30 | -0.81% |
| Fidelity MSCI Energy Index ETF (FENY) | |||